site stats

Cytokinetics 10-k

WebFeb 17, 2024 · Cytokinetics ( NASDAQ: CYTK) is a company dedicated to improving patient health and quality of life by developing muscle biology-based medications. Their lead drug candidate, omecamtiv mecarbil,... WebCytokinetics is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for people with debilitating diseases in which muscle performance is compromised and/or declining. A leader in muscle biology research with ...

Cytokinetics Reports Second Quarter 2024 Financial Results

Web11 rows · Apr 5, 2024 · Cytokinetics’ unparalleled expertise has kept it at the forefront of drug discovery and development for diseases impacting muscle performance. … WebCytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential ... damages of hurricane ian https://summermthomes.com

INVESTOR FAQ Cytokinetics, Inc.

WebCytokinetics, Inc. is a publicly traded biopharmaceutical company based in South San Francisco, California, that develops muscle activators and muscle inhibitors as potential … WebApr 9, 2024 · Shares of CYTK stock opened at $36.42 on Friday. The stock has a fifty day moving average price of $39.79 and a 200 day moving average price of $42.22. The stock has a market cap of $3.48 billion ... WebJul 30, 2014 · Company Provides Updates to Development Programs Focused to Muscle Biology SOUTH SAN FRANCISCO, CA, July 30, 2014 - Cytokinetics, Incorporated (Nasdaq: CYTK) reported total research and development ... birding in central park nyc

Cytokinetics Reports Second Quarter 2024 Financial Results

Category:Cytokinetics pushes on with late-stage study of ALS drug

Tags:Cytokinetics 10-k

Cytokinetics 10-k

Cytokinetics - Wikipedia

Web如果您是机构,请点击下方了解我们为ria、对冲基金、合规官员等提供的服务。

Cytokinetics 10-k

Did you know?

WebApr 29, 2004 · How do I get a copy of Cytokinetics' financial statements, such as Form 10-Q, Form 10-K, Form 8-K or the Annual Report, when available? Our Form 10-Qs, Form 10-Ks, Form 8-Ks and other reports, when available, are listed on the SEC's web site, www.sec.gov , please search on "Cytokinetics" or visit the Investor Center's SEC links … WebApr 10, 2024 · Cytokinetics (CYTK) Dips 20% so Far in 2024 on Setbacks Cytokinetics (CYTK) declines 20% in the year so far as it suffers a regulatory setback for its NDA for omecamtiv mecarbil. 20h ago

Web1 day ago · Cytokinetics Inc is a biotechnology company that develops muscle biology-driven treatments for diseases characterized by reduced muscle function, muscle weakness, and fatigue. The company... WebFeb 27, 2024 · On Feb. 28, the FDA is set to decide on Cytokinetics ’ omecamtiv mecarbil (OM), a novel, selective cardiac myosin activator being evaluated for heart failure with reduced ejection fraction. The regulatory agency accepted the New Drug Application for OM in February 2024 and initially set a target action date of Nov. 30, 2024.

WebApr 3, 2024 · Pictured: FDA Headquarters/Courtesy of Getty Images. Cytokinetics is discontinuing the Phase III COURAGE-ALS trial in amyotrophic lateral sclerosis (ALS) after its candidate, reldesemtiv, failed a planned interim analysis, the company announced Friday.. This decision comes after a Data Monitoring Committee reviewed unblinded data … WebAnalyst Cody Fincher found an unusual item yesterday in Cytokinetics’ (CYTK) 10-K. By David Trainer Contributor. Nov 17, 2015. Cashing In On Cytokinetics, Selling Puts On Wal-Mart.

WebMar 1, 2024 · Cytokinetics Inc (CYTK) 10-K Annual Report Wed Mar 01 2024 Earnings Press Release 10-K Annual Report 10-K YoY Changes Cytokinetics Inc CIK: 1061983 …

WebCytokinetics is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics that modulate muscle function for the … damages of typhoonWebView the 10k annual report for CYTK stock. See latest earnings, revenues, margins, and growth rates. damages of typhoon odetteWebCytokinetics, Inc. is a publicly traded biopharmaceutical company based in South San Francisco, California, that develops muscle activators and muscle inhibitors as potential treatments for people with diseases characterized by impaired or declining muscle function. damages of the dust bowlWebDec 31, 2024 · On November 23, 2024, we announced that Amgen has elected to terminate the Amgen Agreement and thereby end its collaboration with Cytokinetics, effective May 20, 2024, and intends to transition … damage song by rachel wammackWebApr 10, 2024 · The Spinal Muscular Atrophy Medicine market report identifies the most profitable products, end-uses, and evolving distribution channels in each region from 2024 to 2030, projecting a CAGR of 5.5%. damages of typhoon odette in the philippinesWebApr 2, 2024 · In 2024, Cytokinetics reported revenues of $2.0 million for Q4 and $94.6 million for the full year, compared to $55.6 million and $70.4 million in the same periods … damages or injunctive reliefWebApr 10, 2024 · Share This Article. / EIN News / -- SOUTH SAN FRANCISCO, Calif., April 10, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to participate in a fireside chat at the 22 nd Annual Needham Virtual Healthcare Conference … birding in costa rica best time of year